NCT02084420

Efficacy/Safety Study as H. Pylori Eradication of Triple Therapy for 7 Days Treatment

PhaseⅢ Study of A Multicenter, Randomized, Double-blind, Active-controlled to Evaluate of Efficacy /Safety as H. Pylori Eradication Effect Between Ilaprazole/Pantoprazole

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 323 (actual)
• Sponsor: Il-Yang Pharm. Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 74 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate of efficacy and safety as H.pylori eradiation effect between Ilaprazole and Pantoprazole triple therapy for 7 days treatment in Gastric and/or Duodenal ulcer patients with H.pylori positive infection.

Detailed description

This study is to evaluate of efficacy and safety as H.pylori eradiation effect between Ilaprazole and Pantoprazole triple therapy for 7 days treatment in Gastric and/or Duodenal ulcer patients with H.pylori positive infection.

Conditions

• Peptic Ulcer

Interventions

Type	Name	Description
DRUG	Ilaprazole	10mg 2 BID( 2 times / day), before breakfast and dinner
DRUG	Pantoprazole	40mg, BID(2 times / day), before breakfast and dinner

Timeline

• Start date: 2012-12-01
• Primary completion: 2014-01-01
• Completion: 2014-01-01
• First posted: 2014-03-12
• Last updated: 2014-06-03

Locations

18 sites across 1 country: South Korea